Progress reported on understanding why Hispanic children are more likely to develop acute lymphoblastic leukemia and to die of the disease.
St. Jude Children’s Research Hospital honored as recipient of the 2019 Microsoft Health Innovation Awards
St. Jude Children’s Research Hospital announced it has been named a recipient of Microsoft Corp.’s 2019 Health Innovation Awards.
A time-consuming issue for clinicians is assessing drug alerts in EHR systems. Researchers evaluated alerts and found ways to safely reduce alert overrides by 40 percent.
The study reports how two unexpected partners, the proteins UTX and 53BP1, link up to regulate a brain development program comprising hundreds of genes.
Survey results should help health system leaders and patient safety experts dedicate resources to improve safety and clinical outcomes in pediatric health care.
Children with hypodiploid acute lymphoblastic leukemia fare better when minimal residual disease is used to guide treatment.
Research led by St. Jude Children's Research Hospital means more than 90 percent of the most common cases of childhood cancer can now be classified by subtype, an advance likely to fuel precision medicine.
Investigators studied the effects of the H3 K27M mutation, and revealed its impact on mutations that are known drivers of DIPGs.
Read about the newly identified subset of helper T 17 immune cells that suggest a novel approach for taming chronic inflammation.
Scientific discovery by St. Jude group could lead to new pathway for cancer treatment and understanding of ALS.
Explore more research news
More Research News
Clinical Trials Alerts
Our e-newsletter for clinicians offers updates on St. Jude open clinical trials and research news.
Courageous patients. Resolute doctors. Caring staff. Inventive scientists. Their voices come alive in Promise magazine.
Follow Us on Social Media
Connect with @stjuderesearch to keep up with our latest science and medical news. More about St. Jude social media.
Browse all scientific publications by St. Jude investigators.